Biologics for Non-Cancer Dermatological Diseases: Analysis on China’s Clinical Trial Registration Trend From 2016 to 2020

Background: In the past 5 years, China has quickly followed US’s steps to approve the new drug application of biologics for dermatological diseases. There is an increasing interest in the current biologic landscape and further potentials in China. Our study aims to analyze features of clinical trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Beibei, Liu, Yi, Li, Jing, Ni, Qi, Yin, Zheng, Zhu, Junli, Chen, Ken, Yang, Xueyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068892/
https://www.ncbi.nlm.nih.gov/pubmed/35529441
http://dx.doi.org/10.3389/fphar.2022.817065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068892/
https://www.ncbi.nlm.nih.gov/pubmed/35529441
http://dx.doi.org/10.3389/fphar.2022.817065

Ejemplares similares